TOKYO, Feb 7 (Reuters) - U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of ...

Bain Capital is making its latest biotech bid in Japan, where it plans to acquire Mitsubishi Tanabe Pharma Corp. The Boston-based private investment firm is buying Tanabe Pharma from Mitsubishi ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), setting up one of the largest private equity buyouts in Japan's healthcare ...

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease.

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

Mitsubishi Tanabe Pharma and bluebird bio were both bought by investors during the month, while private equity firms ...

Dwelling on what the future may hold can create an unbearable fear.” Through Mitsubishi Tanabe Pharma America’s Share Your Story program, people living with ALS and their caregivers can share ...